Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems, Inc. (Nasdaq: TIVC) generates news that reflects its evolution into a diversified immunotherapeutics and health technology company. This page aggregates coverage of Tivic’s progress in biologics, bioelectronic medicine and contract development and manufacturing, giving investors and observers a single place to review its latest corporate announcements.
Much of Tivic’s recent news flow centers on Entolimod™, its lead Toll-like Receptor 5 (TLR5) agonist drug candidate for acute radiation syndrome (ARS) and related conditions. Articles highlight milestones such as cell line verification, large-scale manufacturing runs, and steps toward current Good Manufacturing Practice (cGMP) production in preparation for a potential Biologics License Application (BLA). Releases also discuss Entolimod’s Fast Track and Orphan Drug designations, its development under the FDA’s Animal Rule, and animal data showing effects on survival, gastrointestinal recovery and hematopoiesis after radiation exposure.
Another major theme in Tivic news is its acquisition of manufacturing and development assets and the launch of Velocity Bioworks™, a wholly owned CDMO subsidiary. Coverage describes how Velocity Bioworks is expected to support Tivic’s own biologics pipeline and offer development and manufacturing services to third-party biotech companies, creating additional revenue opportunities and reducing reliance on external manufacturers.
Visitors will also find updates on Tivic’s bioelectronic program, including results from a clinical optimization trial of non-invasive cervical vagus nerve stimulation conducted with The Feinstein Institutes for Medical Research at Northwell Health. These stories detail how personalized stimulation parameters can influence autonomic measures such as heart rate variability.
In addition, Tivic regularly reports on its interactions with government and industry stakeholders, including BARDA TechWatch meetings, participation in the Military Health System Research Symposium, and conference presentations outlining its strategic transformation. For investors tracking TIVC, this news feed offers a consolidated view of clinical, manufacturing, partnership and capital markets developments.
Summary not available.
Tivic Health Systems, Inc. (TIVC) has completed an underwritten public offering, issuing 20,000,000 shares of common stock at $0.25 each, raising approximately $5 million. The underwriters also have a 45-day option for an additional 3,000,000 shares. The funds will primarily support the expansion of their ClearUP® product for sinus relief and cover clinical and regulatory expenses for future products. While Tivic is exploring potential strategic investments, no definitive agreements are currently in place. The registration statement for this offering was effective as of February 8, 2023, with the prospectus filed on February 10, 2023.
Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, announced a public offering of 20 million shares at $0.25 each, aiming for approximately $5 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase an additional 3 million shares. Proceeds will be used for expanding sales of its product ClearUP® for sinus relief and for clinical and regulatory costs related to new product candidates. The offering is expected to close on February 13, 2023, subject to standard conditions.
Tivic Health Systems, Inc. (TIVC), recognized as the Most Pioneering Bioelectronic Medicine Company of 2022 by Global Health & Pharma, emphasizes the growing field of bioelectronic medicine. CEO Jennifer Ernst highlighted the shift from traditional drug therapeutics to innovative electronic solutions for chronic conditions. The company's ClearUP device, a non-invasive treatment for sinus pain, has earned accolades as the Most Innovative Sinus Relief Solution for two consecutive years. Tivic Health's commitment to evidence-based, non-invasive therapies positions it as a leader in the evolving healthcare landscape.
Tivic Health Systems (Nasdaq: TIVC) has mutually terminated its agreement with Reliefband Technologies regarding the acquisition of the Reliefband product line, initially announced on October 7, 2022. CEO Jennifer Ernst cited volatile capital market conditions as a primary reason for this decision. Despite the setback, the relationship between the two companies remains positive, and Tivic is focused on accelerating sales of its ClearUP product while exploring other growth opportunities.
Tivic Health Systems (TIVC) has hired ALOM Technologies Corporation to enhance its supply chain management, aiming for cost improvements and scalable growth in the bioelectronic medicine sector. ALOM will manage inventory, logistics, and fulfillment from its 19 global locations. This partnership follows a recent agreement with Microart Services Inc. to significantly reduce manufacturing costs by 70% for certain components. Tivic has also increased the MSRP for its ClearUP products by $20 to improve margins.
Tivic Health Systems, Inc. (TIVC) reported a 72% revenue increase in Q3 2022, totaling $477,000, driven by a 130% rise in direct-to-consumer unit sales. Year-to-date revenue increased 65% to $1.4 million, with gross margins improving 22%. The company announced a $33.5 million acquisition of Reliefband Technologies to expand its product offerings, alongside a partnership with Microart Services to reduce manufacturing costs. However, research and development expenses rose significantly, contributing to a net loss of $2.6 million for the quarter.
Tivic Health Systems, Inc. (TIVC) announced it has entered a non-exclusive manufacturing agreement with Microart Services Inc. This partnership aims to significantly reduce product manufacturing and shipping costs. COO Ryan Sabia emphasized that the agreement offers advantageous pricing and enhances scalability while maintaining North American-based production. Tivic Health focuses on bioelectronic medicine, delivering non-invasive treatments for inflammation and related conditions.
Tivic Health, a health technology company focused on bioelectronic medicine, will showcase its FDA-approved ClearUP device at HLTH from November 13-16 in Las Vegas. ClearUP treats sinus pain and congestion caused by colds and allergies. Recently, Tivic announced a definitive agreement to acquire the Reliefband product line for nausea treatment, integrating wearable FDA-cleared therapeutics. The firm aims to enhance consumer awareness of bioelectronic therapies, backed by clinical studies indicating significant symptom reduction.
Tivic Health Systems, a commercial-phase health technology company, is set to announce its third-quarter 2022 financial results via conference call and webcast on November 14, 2022, at 1:30 PM PT.
Shareholders can submit questions until 5:00 PM ET on November 11, 2022. The company specializes in non-invasive bioelectronic treatments aimed at inflammation and related conditions. For more details, visit Tivic Health.